Tuesday, December 4th, 2007...7:21 am
Cleveland BioLabs Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With … (Marketwire via Yahoo! Finance)
Jump to Comments
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure … (Marketwire via Yahoo! Finance) Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage At 48 Hours Post-Exposure … (Medical News Today) Cleveland BioLabs CEO to Share Ongoing Development Strategy at BIO CEO and Investor Conference (Marketwire via Yahoo! Finance) Cleveland BioLabs CEO to Present at Roth Capital 20th Annual OC Growth Stock Conference (Marketwire via Yahoo! Finance) Cleveland BioLabs Not Selected for Defense Contract Award (Marketwire via Yahoo! Finance)
Cleveland BioLabs, Inc. today announced results of a primate study demonstrating the efficacy of Protectan CBLB502 as a mitigator of hematopoietic damage up to 48 hours post-radiation exposure.
Full story at cleveland-akron news
Share your Opinion